FDA Stresses Importance Of Fair Balance; Warning Letters Continue To Climb In 2009
This article was originally published in The Pink Sheet Daily
Executive Summary
Drug makers should “be wary” when making promotional claims, McDermott Will & Emery’s Friede cautions.
You may also be interested in...
FDA Declares Pox On Both Houses In Enforcement Letters For Curosurf, Infasurf
In separate “notice of violation” letters issued Oct. 31 but posted several days apart, FDA rejected superiority claims on the part of Cornerstone Therapeutics and Ony for their respiratory distress syndrome drugs.
FDA's Advertising Letters Continue To Grow, Both In Volume And Depth
FDA's Division of Drug Marketing, Advertising and Communication appears to be shifting the way it writes citations to firms, increasing not just the number of letters it sends, but the number of problems it lists within each letter
FDA's Advertising Letters Continue To Grow, Both In Volume And Depth
FDA's Division of Drug Marketing, Advertising and Communication appears to be shifting the way it writes citations to firms, increasing not just the number of letters it sends, but the number of problems it lists within each letter